{
    "body": "How is oprozomib administered?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24915039", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24471924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22763387", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24712303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22929803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24103732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24239172"
    ], 
    "ideal_answer": [
        "Oprozomib is administered orally."
    ], 
    "exact_answer": [
        "Orally"
    ], 
    "type": "factoid", 
    "id": "56ecfd572ac5ed1459000002", 
    "snippets": [
        {
            "offsetInBeginSection": 715, 
            "offsetInEndSection": 802, 
            "text": "Further, new orally administered second-generation PI oprozomib is being investigated. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24712303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 123, 
            "offsetInEndSection": 254, 
            "text": "Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24915039", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 673, 
            "offsetInEndSection": 917, 
            "text": "This review provides an overview of the role of oral proteasome inhibitors including Marizomib, Oprozomib, Delanzomib, chemical proteasome inhibitors, and cinnabaramides, in the therapy of MM, focusing on developments over the past five years. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239172", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 725, 
            "offsetInEndSection": 1071, 
            "text": "In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24471924", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 796, 
            "offsetInEndSection": 882, 
            "text": "Further, new orally administered second-generation PI oprozomib is being investigated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24712303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1068, 
            "offsetInEndSection": 1414, 
            "text": "In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24471924", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1225, 
            "offsetInEndSection": 1365, 
            "text": "We concluded that based on its activity and oral bioavailability, oprozomib merits further investigation in an animal GvHD prevention model.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24103732", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 540, 
            "offsetInEndSection": 716, 
            "text": "Carfilzomib and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following continual or transient treatment mimicking in vivo pharmacokinetics.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22763387", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 253, 
            "offsetInEndSection": 384, 
            "text": "Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24915039", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 715, 
            "offsetInEndSection": 800, 
            "text": "Further, new orally administered second-generation PI oprozomib is being investigated", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24712303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 725, 
            "offsetInEndSection": 1070, 
            "text": "In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24471924", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 174, 
            "text": "The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22763387", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 123, 
            "offsetInEndSection": 428, 
            "text": "Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors. However, the mechanisms of acquired resistance to carfilzomib and oprozomib are incompletely understood, and effective strategies for overcoming this resistance are needed. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24915039", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 366, 
            "offsetInEndSection": 543, 
            "text": "Carfilzomib and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following continual or transient treatment mimicking in vivo pharmacokinetics. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22763387", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 123, 
            "offsetInEndSection": 255, 
            "text": "Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24915039", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 725, 
            "offsetInEndSection": 802, 
            "text": "new orally administered second-generation PI oprozomib is being investigated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24712303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 798, 
            "offsetInEndSection": 1072, 
            "text": "including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24471924", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 124, 
            "offsetInEndSection": 428, 
            "text": "Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors. However, the mechanisms of acquired resistance to carfilzomib and oprozomib are incompletely understood, and effective strategies for overcoming this resistance are needed.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24915039", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 969, 
            "offsetInEndSection": 1234, 
            "text": "Finally, we found that DC incubation with the drug(s) enhanced I\u03baB expression and that oprozomib inhibited NF-\u03baB expression. We concluded that based on its activity and oral bioavailability, oprozomib merits further investigation in an animal GvHD prevention model.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24103732", 
            "endSection": "abstract"
        }
    ]
}